Advertisement
Advertisement

TLSI

TLSI logo

TriSalus Life Sciences, Inc. Common Stock

3.94
USD
Sponsored
-0.07
-1.87%
Mar 26, 14:41 UTC -4
Open

TLSI Earnings Reports

Positive Surprise Ratio

TLSI beat 3 of 9 last estimates.

33%

Next Report

Date of Next Report
May 18, 2026
Estimate for Q1 26 (Revenue/ EPS)
$10.65M
/
-$0.15
Implied change from Q4 25 (Revenue/ EPS)
-19.36%
/
-28.57%
Implied change from Q1 25 (Revenue/ EPS)
+16.17%
/
-61.54%

TriSalus Life Sciences, Inc. Common Stock earnings per share and revenue

On Jan 12, 2026, TLSI reported earnings of -0.21 USD per share (EPS) for Q4 25, missing the estimate of -0.13 USD, resulting in a -56.37% surprise. Revenue reached 13.21 million, compared to an expected 12.94 million, with a 2.08% difference. The market reacted with a +1.21% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.15 USD, with revenue projected to reach 10.65 million USD, implying an decrease of -28.57% EPS, and decrease of -19.36% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
logo
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
logo
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
logo
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
logo
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
logo
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
logo
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
For Q4 2025, TriSalus Life Sciences, Inc. Common Stock reported EPS of -$0.21, missing estimates by -56.37%, and revenue of $13.21M, 2.08% above expectations.
The stock price moved up 1.21%, changed from $5.80 before the earnings release to $5.87 the day after.
The next earning report is scheduled for May 18, 2026.
Based on -- analysts, TriSalus Life Sciences, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of $10.65M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement